Trial Profile
A Randomized, Double-Blind, Parallel Group Study of the Pharmacokinetics, Safety, and Tolerability of Two Different SAR231893 Drug Products After Administration of a Single Subcutaneous Dose to Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- 16 Jul 2012 Actual end date (1 Jul 2012) added as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 May 2012 Planned end date changed from 1 Jun 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.